Halofuginone and muscular dystrophy

Histology and Histopathology

Volumn 26, Issue 1, 2011, Pages 135-146

  Pines, Mark ^a   Halevy, Orna ^b  

^a VOLCANI CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

Collagen; Fibrosis; Smad3; TGF

Indexed keywords

COLLAGEN; HALOFUGINONE; PIPERIDINE DERIVATIVE; QUINAZOLINONE DERIVATIVE; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL; ANIMAL MUSCULAR DYSTROPHY; ARTICLE; BIOLOGICAL MODEL; DRUG EFFECT; FIBROSIS; GENE EXPRESSION PROFILING; GENETICS; HUMAN; METABOLISM; MOUSE; MUSCULAR DYSTROPHY; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ANIMALS; COLLAGEN; FIBROSIS; GENE EXPRESSION PROFILING; HUMANS; MICE; MICE, INBRED MDX; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; MUSCULAR DYSTROPHIES; MUSCULAR DYSTROPHY, ANIMAL; PHOSPHORYLATION; PIPERIDINES; QUINAZOLINONES; SIGNAL TRANSDUCTION; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA;

EID: 78651258934     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (100)

1. Alexakis C., Partridge T. and Bou-Gharios G. (2007). Implication of the satellite cell in dystrophic muscle fibrosis: a self-perpetuating mechanism of collagen overproduction. Am. J. Physiol. Cell. Physiol. 293, C661-C669.
2. Andreetta F., Bernasconi P., Baggi F., Ferro P., Oliva L., Arnoldi E., Cornelio F., Mantegazza R. and Confalonieri P. (2006). Immunomodulation of TGF-beta1 in mdxmouse inhibits connective tissue proliferation in diaphragm but increases inflammatory response: implications for antifibrotic therapy. J. Neuroimmunol. 175, 77-86.
3. Bakay M., Zhao P., Chen J. and Hoffman E. P. (2002). A web-accessible complete transcriptome of normal human and DMD muscle. Neuromuscular Disord. 12, S125-S141.
4. Bernasconi P., Torchiana E., Confalonieri P., Brugnoni R., Barresi R., Mora M., Cornelio F., Morandi L. and Mantegazza R. (1995). Expression of transforming growth factor-beta 1 in dystrophic patient muscles correlates with fibrosis. Pathogenetic role of a fibrogenic cytokine. J. Clin. Invest. 96, 1137-1144.
5. Bernasconi P., Di Blasi C., Mora M., Morandi L., Galbiati S., Confalonieri P., Cornelio F. and Mantegazza R. (1999). Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscular Disord. 9, 28-33.
6. Besse S., Allamand V., Vilquin J. T., Li Z., Poirier C., Vignier N., Hori H., Guénet J. L. and Guicheney P. (2003). Spontaneous muscular dystrophy caused by a retrotransposal insertion in the mouse laminin alpha2 chain gene. Neuromuscular Disord. 13, 216-222.
7. Blaauw B., Mammucari C., Toniolo L., Agatea L., Abraham R., Sandri M., Reggiani C. and Schiaffino S. (2008). Akt activation prevents the force drop induced by eccentric contractions in dystrophin-deficient skeletal muscle. Hum. Mol. Genet. 17, 3686-3696.
8. Blaauw B., Canato M., Agatea L., Toniolo L., Mammucari C., Masiero E., Abraham R., Sandri M., Schiaffino S. and Reggiani C. (2009). Inducible activation of Akt increases skeletal muscle mass and force without satellite cell activation. FASEB J. 23, 3896-3905.
9. Bostick B., Yue Y., Long C., Marschalk N., Fine D. M., Chen J. and Duan D. (2009). Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdxmice. Mol. Ther. 17, 253-261.
10. Bruck R., Genin O., Aeed H., Alexiev R., Nagler A. and Pines M. (2001). Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology 33, 379-386.
11. Bushby K. M. (2000). Dysferlin and muscular dystrophy. Acta Neurol. Belg. 100, 142-145.
12. Bushby K. M. (2009). Diagnosis and management of the limb girdle muscular dystrophies. Pract. Neurol. 9, 314-323.
13. Carlson M. E., Hsu M. and Conboy I. A. (2008). Imbalance between pSmad3 and Notch induces CDK inhibitors in old muscle stem cells, Nature 45, 528-532.
14. Chan Y. S., Li Y., Foster W., Horaguchi T., Somogyi G., Fu F. H. and Huard J. (2003). Antifibrotic effects of suramin in injured skeletal muscle after laceration. J. Appl. Physiol. 95, 771-780.
15. Cohn R. D., van Erp C., Habashi J. P., Soleimani A. A., Klein E. C., Lisi M. T., Gamradt M., ap Rhys C. M., Holm T. M., Loeys B. L., Ramirez F., Judge D. P., Ward C. W. and Dietz H. C. (2007). Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat. Med. 13, 204-210.
16. Coirault C., Pignol B., Cooper R. N., Butler-Browne G., Chabrier P. E. and Lecarpentier Y. (2003). Severe muscle dysfunction precedes collagen tissue proliferation in mdx mouse diaphragm. J. Appl. Physiol. 94, 1744-1750.
17. Coulton G. R., Morgan J. E., Partridge T. A. and Sloper J. C. (1988). The mdx mouse skeletal muscle myopathy: I. A histological, morphometric and biochemical investigation. Neuropathol. Appl. Neurobiol. 14, 53-70.
18. Dalkilic I. and Kunkel L. M. (2003). Muscular dystrophies: genes to pathogenesis. Curr. Opin. Genet. Dev. 13, 231-238.
19. Davies K. E. and Nowak K. J. (2006). Molecular mechanisms of muscular dystrophies: old and new players. Nat. Rev. Mol. Cell Biol. 10, 762-773.
20. Deconinck N. and Dan B. (2007). Pathophysiology of duchenne muscular dystrophy: current hypotheses. Pediatr. Neurol. 36, 1-7.
21. de Jonge M. J., Dumez H., Verweij J., Yarkoni S., Snyder D., Lacombe D., Marréaud S., Yamaguchi T., Punt C. J., van Oosterom A. and EORTC New Drug Development Group (NDDG) (2006). Phase I and pharmacokinetic study of halofuginone, an oral quinazolinone derivative in patients with advanced solid tumours. Eur. J. Cancer 42, 1768-1774.
22. DeLuca A., Pierno S., Liantonio A., Cetrone M., Camerino C., Fraysse B., Mirabella M., Servidei S., Ruegg U. T. and Camerino D. C. (2003). Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J. Pharmacol. Exp. Ther. 304, 453-472.
23. Desguerre I., Mayer M., Leturcq F., Barbet J. P., Gherardi R. K. and Christov C. (2009). Endomysial fibrosis in Duchenne muscular dystrophy: a marker of poor outcome associated with macrophage alternative activation. J. Neuropathol. Exp. Neurol. 68, 762-773.
24. Dunace V. C., Stephens H. R., Dunn M., Bailey A. J. and Dubowitz V. (1980). A role for collagen in the pathogenesis of muscular dystrophy? Nature 284, 470-472.
25. Finsterer J. and Stollberger C. (2003). The heart in human dystrophinopathies. Cardiology 99, 1-19.
26. Genin O., Rechavi G., Nagler A., Ben-Itzhak O., Nazemi K. and Pines M. (2008). Myofibroblasts in pulmonary and brain metastases of alveolar soft-part sarcoma: a novel target for treatment? Neoplasia 10, 940-948.
27. Gnainsky Y., Kushnirsky Z., Bilu G., Hagai Y., Genina O., Volpin H., Bruck R., Spira G., Nagler A., Kawada N., Yoshizato K., Reinhardt D. P., Libermann T. A. and Pines M. (2007). Gene expression during chemically induced liver fibrosis: effect of halofuginone on TGF-beta signaling. Cell Tissue Res. 328, 153-166.
28. Goldspink G., Fernandes K., Williams P. E. and Wells D. J. (1994). Agerelated changes in collagen gene expression in the muscles of mdx dystrophic and normal mice. Neuromuscular Disord. 4, 183-191.
29. Gorospe J. R., Tharp M., Demitsu T. and Hoffman E. P. (1994). Dystrophin-deficient myofibers are vulnerable to mast cell granuleinduced necrosis. Neuromuscular Disord. 4, 325-333.
30. Gosselin L. E. and Martinez D. A. (2004). Impact of TNF-alpha blockade on TGF-beta1 and type I collagen mRNA expression in dystrophic muscle. Muscle Nerve 30, 244-246.
31. Gosselin L. E. and Williams J. E. (2006). Pentoxifylline fails to attenuate fibrosis in dystrophic (mdx) diaphragm muscle. Muscle Nerve 33, 820-823.
32. Gosselin L. E., Williams J. E., Personius K. and Farkas G. A. (2007). A comparison of factors associated with collagen metabolism in different skeletal muscles from dystrophic (mdx) mice: impact of pirfenidone. Muscle Nerve 35, 208-216.
33. Guo L. T., Zhang X. U., Kuang W., Xu H., Liu L. A., Vilquin J. T., Miyagoe-Suzuki Y., Takeda S., Ruegg M. A., Wewer U. M. and Engvall E. (2003). Laminin alpha2 deficiency and muscular dystrophy; genotype-phenotype correlation in mutant mice. Neuromuscular Disord. 13, 207-215.
34. Halevy O., Nagler A., Levi-Schaffer F., Genin O. and Pines M. (1996). Inhibition of collagen type I synthesis by skin fibroblasts of graft versus host disease and scleroderma patients: effect of halofuginone. Biochem. Pharmacol. 52, 1057-1063.
35. Hantai D., Labat-Robert J., Grimaud J. A. and Fardeau M. (1985). Fibronectin, laminin, type I, III and IV collagens in Duchenne's muscular dystrophy, congenital muscular dystrophies and congenital myopathies: an immunocytochemical study. Connect. Tissue Res. 13, 273-281.
36. Hartel J. V., Granchelli J. A., Hudecki M. S., Pollina C. M. and Gosselin L. E. (2001). Impact of prednisone on TGF-beta1 and collagen in diaphragm muscle from mdxmice. Muscle Nerve 24, 428-432.
37. Haslett J. N., Sanoudou D., Kho A. T., Bennett R. R., Greenberg S. A., Kohane I. S., Beggs A. H. and Kunkel L. M. (2002). Gene expression comparison of biopsies from Duchenne muscular dystrophy (DMD) and normal skeletal muscle. Proc. Natl. Acad. Sci. USA 99, 15000-15005.
38. Haslett J. N., Sanoudou D., Kho A. T., Han M., Bennett R. R., Kohane I. S., Beggs A. H. and Kunkel L. M. (2003). Gene expression profiling of Duchenne muscular dystrophy skeletal muscle. Neurogenetics 4, 163-171.
39. Heydemann A., Ceco E., Lim J. E., Hadhazy M., Ryder P., Moran J. L., Beier D. R., Palmer A. A. and McNally E. M. (2009). Latent TGF-betabinding protein 4 modifies muscular dystrophy in mice. J. Clin. Invest. 119, 3703-3712.
40. Hino M., Hamada N., Tajika Y., Funayama T., Morimura Y., Sakashita T., Yokota Y., Fukamoto K., Kobayashi Y. and Yorifuji H. (2009). Insufficient membrane fusion in dysferlin-deficient muscle fibers after heavy-ion irradiation. Cell Struct. Funct. 34, 11-15.
41. Huebner K. D., Jassal D. S., Halevy O., Pines M. and Anderson J. E. (2008). Functional resolution of fibrosis in mdx mouse dystrophic heart and skeletal muscle by halofuginone. Am. J. Physiol. Heart Circ. Physiol. 294, H1550-H1561.
42. Ionasescu V., Lara-Braud C., Zellweger H., Ionasescu R. and Burmeister L. (1977). Fibroblast cultures in Duchenne muscular dystrophy. Alterations in synthesis and secretion of collagen and noncollagen proteins. Acta Neurol. Scand. 55, 407-417.
43. Ishii H., Choudhuri R., Mathias A., Sowers A. L., Flanders K. C., Cook J. A. and Mitchell J. B. (2009). Halofuginone mediated protection against radiation-induced leg contracture. Int. J. Oncol. 35, 315-319.
44. Ishitobi M., Haginoya K., Zhao Y., Ohnuma A., Minato J., Yanagisawa T., Tanabu M., Kikuchi M. and Iinuma K. (2000). Elevated plasma levels of transforming growth factor beta1 in patients with muscular dystrophy. Neuroreport 11, 4033-4035.
45. Jin Y., Murakami N., Saito Y., Goto Y., Koishi K. and Nonaka I. (2000). Expression of MyoD and myogenin in dystrophic mice, mdxand dy, during regeneration. Acta Neuropathol. 99, 619-627.
46. Klinge L., Aboumousa A., Eagle M., Hudson J., Sarkozy A., Vita G., Charlton R., Roberts M., Straub V., Barresi R., Lochmüller H. and Bushby K. (2010). New aspects on patients affected by dysferlin deficient muscular dystrophy. J. Neurol. Neurosurg. Psychiatry 81, 946-953.
47. Kobayashi K., Izawa T., Kuwamura M. and Yamate J. (2010). The distribution and characterization of skeletal muscle lesions in dysferlin-deficient SJL and A/J mice. Exp. Toxicol. Pathol. 62, 509-517.
48. Krupnick A. S., Zhu J., Nguyen T., Kreisel D., Balsara K. R., Lankford E. B., Clark C. C., Levine S., Stedman H. H. and Shrager J. B. (2003). Inspiratory loading does not accelerate dystrophy in mdx mouse diaphragm: implications for regenerative therapy. J. Appl. Physiol. 94, 411-419.
49. Kuang W., Xu H., Vachon P. H., Liu L., Loechel F., Wewer U. M. and Engvall E. (1998). Merosin-deficient congenital muscular dystrophy. Partial genetic correction in two mouse models. J. Clin. Invest. 102, 844-852.
50. Levi-Schaffer F., Nagler A., Slavin S., Knopov V. and Pines M. (1996). Inhibition of collagen synthesis and changes in skin morphology in murine graft-versus-host disease and tight skin mice: effect of halofuginone. J. Invest. Dermatol. 106, 84-88.
51. Lewis C., Carberry S. and Ohlendieck K. (2009). Proteomic profiling of x-linked muscular dystrophy. J. Muscle Res. Cell. Motil. 30, 267-269.
52. MacPike A. D. and Meier H. (1976). Comparison of dy and dy2J, two alleles expressing forms of muscular dystrophy in the mouse. Proc. Soc. Exp. Biol. Med. 151, 670-672.
53. Marotta M., Ruiz-Roig C., Sarria Y., Peiro J. L., Nuñez F., Ceron J., Munell F. and Roig-Quilis M. (2009). Muscle genome-wide expression profiling during disease evolution in mdxmice. Physiol. Genomics 37, 119-132.
54. Marques M. J., Oggiam D. S., Barbin I. C., Ferretti R. and Santo Neto H. (2009). Long-term therapy with deflazacort decreases myocardial fibrosis in mdxmice. Muscle Nerve 40, 466-468.
55. Marshall P. A., Williams P. E. and Goldspink G. (1989). Accumulation of collagen and altered fiber-type ratios as indicators of abnormal muscle gene expression in the mdx dystrophic mouse. Muscle Nerve 12, 528-537.
56. McGaha T. L., Kodera T., Phelps R., Spiera H., Pines M. and Bona C. (2002a). Effect of halofuginone on the development of tight skin (TSK) syndrome. Autoimmunity 35, 277-282.
57. McGaha T. L., Phelps R. G., Spiera H. and Bona C. (2002b). Halofuginone, an inhibitor of type-I collagen synthesis and skin sclerosis, blocks transforming-growth-factor-beta-mediated Smad3 activation in fibroblasts. J. Invest. Dermatol. 118, 461-470.
58. McNally E. M. (2007). New approaches in the therapy of cardiomyopathy in muscular dystrophy. Ann. Rev. Med. 58, 75-88.
59. McNally E. M. and Pytel P. (2007). Muscle diseases: the muscular dystrophies. Annu. Rev. Pathol. Mech. Dis. 2, 87-109.
60. Meier H. and MacPike AD. (1977). Myopathies caused by three mutations of the mouse. J. Hered. 68, 383-385.
61. Melone M. A., Peluso G., Petillo O., Galderisi U. and Cotrufo R. (1999). Defective growth in vitro of Duchenne Muscular Dystrophy myoblasts: the molecular and biochemical basis. J. Cell. Biochem. 76, 118-132.
62. Morrison J., Lu Q. L., Pastoret C., Partridge T. and Bou-Gharios G. (2000). T-cell-dependent fibrosis in the mdxdystrophic mouse. Lab. Invest. 80, 881-891.
63. Murakami N., McLennan I. S., Nonaka I., Koishi K., Baker C. and Hammond-Tooke G. (1999). Transforming growth factor-beta2 is elevated in skeletal muscle disorders. Muscle Nerve 22, 889-898.
64. Nagler A. and Pines M. (1999). Topical treatment of cutaneous chronic graft versus host disease (cGvHD) with halofuginone: a novel inhibitor of collagen type I synthesis. Transplantation 68, 1806-1809.
65. Nagler A., Rivkind A. I., Raphael J., Levi-Schaffer F., Genina O., Lavelin I. and Pines M. (1998). Halofuginone-an inhibitor of collagen type I synthesis-prevents post-operation abdominal adhesions formation. Ann. Surg. 227, 575-582.
66. Nagler A., Genina O., Lavelin I., Ohana M. and Pines M. (1999). Halofuginone-an inhibitor of collagen type I synthesis-prevents formation of post-operative adhesions formation in the rat uterine horn model. Am. J. Obstet. Gyn. 180, 558-563.
67. Nagler A., Gofrit O., Ohana M., Pode D., Genina O. and Pines M. (2000). The effect of halofuginone, an inhibitor of collagen type I synthesis, on urethral stricture formation in vivo and in vitro study in a rat model. J. Urol. 164, 1776-1780.
68. Nevo Y., Halevy O., Genin O., Turgeman T., Harel M., Biton E., Reif S. and Pines M. (2010). Inhibition of fibrosis in laminin-α2-deficient congenital muscular dystrophy mice: effect of halofuginone. Muscle Nerve 42, 218-229.
69. Nyska M., Nyska A., Rivlin E., Porat S., Pines M., Shoshan S. and Nagler, A. (1996). Topically applied halofuginone, an inhibitor of collagen type I transcription, reduced peritendinous fibrous adhesions following surgery. Conn. Tissue Res. 34, 97-103.
70. Passerini L., Bernasconi P., Baggi F., Confalonieri P., Cozzi F., Cornelio F. and Mantegazza R. (2002). Fibrogenic cytokines and extent of fibrosis in muscle of dogs with X-linked golden retriever muscular dystrophy. Neuromuscular Disord. 12, 828-835.
71. Pines M. (2008). Targeting TGFß signaling to inhibit fibroblasts activation as a therapy for fibrosis and cancer. Exp. Opin. Drug Dis. 3 (1), 11-20.
72. Pines M. and Nagler A. (1996). Halofuginone-a novel anti-fibrotic therapy. Drug of the Future 21, 569-599.
73. Pines M. and Nagler A. (1998). Halofuginone: a novel antifibrotic therapy. Gen. Pharmacol. 30, 445-450.
74. Pines M., Knopov V., Genin O., Lavelin I. and Nagler A. (1997). Halofuginone, a specific inhibitor of collagen type I synthesis, prevents dimethylnitrosamine-induced liver cirrhosis. J. Hepatol. 27, 391-398.
75. Pines M., Vlodavsky I. and Nagler A. (2000). Halofuginone: from veterinary use to human therapy. Drug Dev. Res. 50, 371-378.
76. Pines M., Domb A., Ohana M., Inbar J., Genina O., Aleviev R. and Nagler A. (2001). Reduction in dermal fibrosis in the tight-skin (Tsk) mouse after local application of halofuginone. Biochem. Pharmacol. 62, 1221-1227.
77. Pines M., Snyder D., Yarkoni S. and Nagler A. (2003). Halofuginone to treat fibrosis in chronic graft versus host disease and scleroderma. Biol. Blood Marrow Transplant. 9, 417-425.
78. Popov Y., Patsenker E., Bauer M., Niedobitek E., Schulze-Krebs A. and Schuppan D. (2006). Halofuginone induces matrix metalloproteinases in rat hepatic stellate cells via activation of p38 and NFkappaB. J. Biol. Chem. 281, 15090-15098.
79. Porter J. D., Khanna S., Kaminski H. J., Rao J. S., Merriam A. P., Richmonds C. R., Leahy P., Li J. and Andrade FH. (2001). Extraocular muscle is defined by a fundamentally distinct gene expression profile. Proc. Natl. Acad. Sci. USA 98, 12062-12067.
80. Porter J. D., Merriam A. P., Leahy P., Gong B. and Khanna S. (2003). Dissection of temporal gene expression signatures of affected and spared muscle groups in dystrophin-deficient (mdx) mice. Hum. Mol. Genet. 12, 1813-1821.
81. Prelle A., Sciacco M., Tancredi L., Fagiolari G., Comi G. P., Ciscato P., Serafini M., Fortunato F., Zecca C., Gallanti A., Chiveri L., Bresolin N., Scarlato G. and Moggio M. (2003). Clinical, morphological and immunological evaluation of six patients with dysferlin deficiency. Acta Neuropathol. (Berl.) 105, 537-542.
82. Qiao C., Li J., Zhu T., Draviam R., Watkins S., Ye X., Chen C., Li J. and Xiao X. (2005). Amelioration of laminin-alpha2-deficient congenital muscular dystrophy by somatic gene transfer of miniagrin. Proc. Natl. Acad. Sci. USA 102, 11999-12004.
83. Quinlan J. G., Hahn H. S., Wong B. L., Lorenz J. N., Wenisch A. S. and Levin L. S. (2004). Evolution of the mdx mouse cardiomyopathy: physiological and morphological findings. Neuromuscular Disord. 14, 491-496.
84. Roffe S., Hagai Y., Pines M. and Halevy O. (2010). Halofuginone inhibits Smad3 phosphorylation via the PI3K/Akt and MAPK/ERK pathways in muscle cells: effect on myotube fusion. Exp. Cell. Res. 316, 1061-1069.
85. Sheffer Y., Leon O., Pinthus J. H., Nagler A., Mor Y., Genin O., Iluz M., Kawada N., Yoshizato K. and Pines M. (2007). Inhibition of fibroblast to myofibroblast transition by halofuginone contributes to the chemotherapy- mediated anti-tumoral effect. Mol. Cancer Ther. 6, 570-577.
86. Spira G., Mawasi N., Paizi M., Anbinder N., Genina O., Alexiev R. and Pines M. (2002). Halofuginone, a collagen type I inhibitor, improves liver regeneration in cirrhotic rats. J. Hepatol. 37, 331-339.
87. Stedman H. H., Sweeney H. L., Shrager J. B., Maguire H. C., Panettieri R. A., Petrof B., Narusawa M., Leferovich J. M., Sladky J. T. and Kelly A. M. (1991). The mdx mouse diaphragm reproduces the degenerative changes of Duchenne muscular dystrophy. Nature 352, 536-539.
88. Sundrud M. S., Koralov S. B., Feuerer M., Calado D. P., Kozhaya A. E., Rhule-Smith A., Lefebvre R. E., Unutmaz D., Mazitschek R., Waldner H., Whitman M., Keller T. and Rao A. (2009). Halofuginone inhibits TH17 cell differentiation by activating the amino acid starvation response. Science 324, 1334-1338.
89. Takaya Y., Tasaka H., Chiba T., Uwai K., Tanitsu M. and Kim H. S. (1999). New type of febrifugine analogues, bearing a quinolizidine moiety, show potent antimalarial activity against plasmodium malaria parasite. J. Med. Chem. 42, 3163-3166.
90. Taniguchi M., Kurahashi H., Noguchi S., Sese J., Okinaga T., Tsukahara T., Guicheney P., Ozono K., Nishino I., Morishita S. and Toda T. (2006). Expression profiling of muscles from Fukuyama-type congenital muscular dystrophy and laminin-alpha 2 deficient congenital muscular dystrophy; is congenital muscular dystrophy a primary fibrotic disease? Biochem. Biophys. Res. Commun. 342, 489-502.
91. Turgeman T., Hagai Y., Huebner K., Jassal D. S., Anderson J., Genin O., Nagler A., Halevy O. and Pines M. (2008). Prevention of muscle fibrosis and improvement in muscle performance in the mdxmouse by halofuginone. Neuromuscular Disord. 18, 857-868.
92. Turk R., Sterrenburg E., de Meijer E. J., van Ommen G. J., den Dunnen J. T. and 't Hoen P. A. (2005). Muscle regeneration in dystrophindeficient mdx mice studied by gene expression profiling. BMC Genomics 6, 98.
93. van Lunteren E., Moyer M. and Leahy P. (2006). Gene expression profiling of diaphragm muscle in alpha2-laminin (merosin)-deficient dy/dy dystrophic mice. Physiol. Genomics 25, 85-95.
94. Vidal B., Serrano A. L., Tjwa M., Suelves M., Ardite E., De Mori R., Baeza-Raja B., Martínez de Lagrán M., Lafuste P., Ruiz-Bonilla V., Jardí M., Gherardi R., Christov C., Dierssen M., Carmeliet P., Degen J. L., Dewerchin M. and Muñoz-Cánoves P. (2008). Fibrinogen drives dystrophic muscle fibrosis via a TGFbeta/alternative macrophage activation pathway. Genes Dev. 22, 1747-1752.
95. Xavier S., Piek E., Fujii M., Javelaud D., Mauviel A., Flanders K. C., Samuni A. M., Felici A., Reiss M., Yarkoni S., Sowers A., Mitchell J. B., Roberts A. B. and Russo A. (2004). Amelioration of radiationinduced fibrosis: inhibition of transforming growth factor-beta signaling by halofuginone. J. Biol. Chem. 279, 15167-15176.
96. Yee K. O., Connolly C. M., Pines M. and Lawler J. (2006). Halofuginone Inhibits Tumor Growth in the Polyoma Middle T Antigen Mouse via a Thrombospondin-1 Independent Mechanism. Cancer Biol. Ther. 5, 218-224.
97. Zanotti S., Gibertini S. and Mora M. (2010). Altered production of extracellular matrix components by muscle-derived Duchenne muscular dystrophy fibroblasts before and after TGF-beta1 treatment. Cell Tiss. Res. 339, 397-410.
98. Zhao Y., Haginoya K., Sun G., Dai H., Onuma A. and Iinuma K. (2003). Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study. J. Pathol. 201, 149-159.
99. Zhu S., Goldschmidt-Clermont P. J. and Dong C. (2004). Transforming growth factor-beta-induced inhibition of myogenesis is mediated through Smad pathway and is modulated by microtubule dynamic stability. Circ. Res. 94, 617-625.
100. Zion O., Genin O., Kawada N., Yoshizato K., Roffe S., Nagler A., Iovanna J. L., Halevy O. and Pines M. (2009). Inhibition of TGFß signaling by halofuginone as a modality for pancreas fibrosis prevention. Pancreas 3, 427-435.